Every material Form 8-K Lyell Immunopharma, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Lyell Immunopharma reported a third-quarter 2026 net loss of $45.5 million, up from $38.8 million a year earlier, as research and development expenses rose to $40.9 million. Cash, cash equivalents and marketable securities fell to $194.0 million from $247.2 million at December 31, 2025, and the company announced an $80.0 million private placement that it says will fund operations into 2028.
Q3 2026 net loss was $45.5 million versus $38.8 million in Q3 2025; the company attributed the increase mainly to higher R&D spending on clinical trial activity.
R&D expenses were $40.9 million versus $28.2 million, while G&A expenses fell to $9.3 million from $10.7 million.
Cash and marketable securities were $194.0 million at September 30, 2026, down from $247.2 million at December 31, 2025.
An $80.0 million private placement was announced in November 2026, with the company expecting cash to last into 2028.
Lyell Immunopharma said it completed the technology transfer of LYL273, its GCC-targeted CAR T-cell candidate, to its LyFE facility in Bothell, Washington, after FDA review of an improved manufacturing process. The company also said additional clinical data from the Phase 1/2 trial in metastatic colorectal cancer and an End-of-Phase 1 meeting with the FDA are now expected in 2027, which pushes out the timeline for those milestones.
Technology transfer to the LyFE facility in Bothell, Washington, completed following FDA review of an improved manufacturing process and updated analytical methods
Dosing of additional patients with the new process continues, with the goal of determining the recommended Phase 2 dose and optimized safety management plan
Additional clinical data and the End-of-Phase 1 meeting with the FDA are now expected in 2027
In June 2026, the company reported that gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxis
Lyell Immunopharma reported a second-quarter 2026 net loss of $44.8 million, up from $42.7 million a year earlier, as research and development spending rose on increased clinical trial activity. The company had $228.0 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it says is sufficient into the third quarter of 2027, and it reiterated that pivotal data from its PiNACLE trial are expected in mid-2027.
Net loss was $44.8 million for the quarter ended June 30, 2026, compared with $42.7 million in the same period of 2025.
R&D expenses rose to $39.5 million from $34.9 million, driven by an $8.8 million increase in research activities and outside services.
Cash, cash equivalents and marketable securities were $228.0 million as of June 30, 2026, down from $247.2 million at December 31, 2025.
Pivotal data from the PiNACLE trial of ronde-cel are expected in mid-2027, with a BLA submission expected to follow in the second half of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lyell Immunopharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →